Cover
Cover | Jun. 01, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | This Current Report on Form 8-K/A is being filed as an amendment (this "Amendment No. 1") to the Current Report on Form 8-K filed by Ironwood Pharmaceuticals, Inc. (the "Company") with the Securities and Exchange Commission on June 7, 2021 (the "Original Report"). In the Original Report, the Company disclosed that, among other events, Thomas McCourt, who previously served as the Company's President and interim Chief Executive Officer was appointed by the Board of Directors (the "Board") as the Company's Chief Executive Officer. This Amendment No. 1 is being filed to provide a description of the severance agreement entered into between the Company and Mr. McCourt on June 22, 2021, in connection with Mr. McCourt's appointment as Chief Executive Officer. Except as set forth herein, this Amendment No. 1 does not amend, modify or update the disclosure contained in the Original Report. |
Document Period End Date | Jun. 1, 2021 |
Entity File Number | 001-34620 |
Entity Registrant Name | IRONWOOD PHARMACEUTICALS, INC. |
Entity Central Index Key | 0001446847 |
Entity Tax Identification Number | 04-3404176 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 100 Summer Street |
Entity Address, Address Line Two | Suite 2300 |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02110 |
City Area Code | 617 |
Local Phone Number | 621-7722 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Class A common stock, $0.001 par value |
Trading Symbol | IRWD |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |